ÈËÆÞÖгöÊÓƵ

Journal Article

1. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK (2023). Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol, JCO2301529. ()
2. Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH (2023). CYP2D6-guided opioid therapy for adults with cancer pain: a randomized implementation clinical trial. Pharmacotherapy. ()
3. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants (2022). Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst, 115(9), 1001-1010. ()
4. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
5. Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S (2023). A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol, 14, 1229823. ()
6. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger AC (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. J Cancer Educ, 38(4), 1353-1362. ()
7. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer, 11(8). ()
8. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA (2023). Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer, 30(8). ()
9. Leiter RE, Varas MTB, Miralda K, Muneton-Castano Y, Furtado G, Revette A, Cronin C, Soares HP, Lopez A, Hayman LL, Lindsay AC, Schrag D, Enzinger AC (2023). Adaptation of a Multimedia Chemotherapy Educational Intervention for Latinos: Letting Patient Narratives Speak for Themselves. J Cancer Educ, 38(4), 1353-1362. ()
10. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C (2021). Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(7), 839-868. ()
11. Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130. ()
12. Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted.    . Cancer.
13. Bergslang E, Halperin D, Dillon, J, Dasari A, Kunz P, Soares HP, Pryma D, Hope T, Soulen M, Mailmain J, Howe, J (2020). NANETS Guide for Neuroendocrine Tumor Patient ÈËÆÞÖгöÊÓƵcare Providers during COVID-19" (the "Work"). Accepted. Pancreas.
14. Al-Toubah T, Schell MJ, Cives M, Zhou JM, Soares HP, Strosberg JR (2019). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 110(5), 377-383. ()
15. Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol, 10(4), 647-687.
16. Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481. ()
17. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 37(12), 1015-1027. ()
18. Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer, 18(1), 665. ()
19. Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials, 68, 7-13. ()
20. Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2017). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289. ()
21. Wainberg ZA, Alsina M, Soares HP, Braa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol, 12(6), 775-785. ()
22. Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66. ()
23. Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7. ()
24. Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther, 14(4), 1014-23. ()
25. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One, 9(12), e114573. ()
26. Rozengurt E, Soares HP, Sinnet-Smith J (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther, 13(11), 2477-88. ()
27. Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45. ()
28. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One, 8(2), e57289. ()
29. Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I (2012). New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev, 10, MR000024. ()
30. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol, 65(6), 602-9. ()
31. Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ (2010). Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol, 64(6), 583-93. ()
32. Soares HP, Lutzky J (2010). Velimogene aliplasmid. Expert Opin Biol Ther, 10(5), 841-51. ()
33. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schnemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7. ()
34. Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schnemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49. ()
35. Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abro MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A (2008). Burnout in cancer professionals: a systematic review and meta-analysis. Eur J Cancer Care (Engl), 17(6), 524-31. ()
36. Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42. ()
37. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008). Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med, 49(3), 480-508. ()
38. Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol, 2(12), 1091-7. ()
39. Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304. ()
40. Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control, 14(2), 160-6. ()
41. Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol, 25(10), 1272-6. ()
42. Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9. ()
43. Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5. ()
44. Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6. ()
45. Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80. ()
46. Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90. ()
47. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Childrens Oncology Group (2005). Are experimental treatments for cancer in ÈËÆÞÖгöÊÓƵren superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295. ()
48. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293(8), 970-8. ()
49. Kumar A, Soares H, Serdarevic F (2005). Totality of evidence: one of the keys to better oncology management. J Oncol Manag, 14(1), 12-4. ()
50. Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24. ()
51. Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6. ()
52. Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J, 122(2), 60-3. ()
53. Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4. ()
54. Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3(3), 201-5. ()
55. Pereira LP, Waisberg J, Andr EA, Zanoto A, Mendes Jnior JP, Soares HP (2002). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6. ()
56. Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54. ()
57. del Giglio A, Soares HP, Caparroz C, Castro PC (2001). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8. ()

Review

1. Naraev BG, Mailman J, Halfdanarson TR, Soares HP, Mittra ES, Hallet J (2023). Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors. [Review]. Expert Rev Anticancer Ther, 23(6), 601-615. ()
2. Chauhan A, Del Rivero J, Ramirez RA, Soares HP, Li D (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. [Review]. Cancers (Basel), 14(21). ()
3. Jacob A, Raj R, Allison DB, Soares HP, Chauhan A (2022). An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN). [Review]. Curr Treat Options Oncol, 23(5), 721-735. ()
4. Egal ESA, Jacenik D, Soares HP, Beswick EJ (2021). Translational challenges in pancreatic neuroendocrine tumor immunotherapy. [Review]. Biochim Biophys Acta Rev Cancer, 1876(2), 188640. ()
5. Hunter LA, Soares HP (2021). Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. [Review]. Cancers (Basel), 13(20). ()

Editorial

1. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR (2020). North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient ÈËÆÞÖгöÊÓƵ Care Providers During COVID-19. Pancreas, 49(6), 723-728. ()

Letter

1. Ryan CE, Saif A, Rocha F, Philip P, Hernandez JM, Ahmad S, Soares H (2022). Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors. [Letter to the editor]. Ann Surg Oncol, 30(3), 1302-1304. ()

Other

1. Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist (26(8), pp. 651-659). England. ()

Huntsman Cancer Institute News

• Ricky’s Ride with Neuroendocrine Pancreatic Cancer
• Ask an Expert: The Truth about Clinical Trials
• Building on the Lifesaving Work of Cancer Research
• Researcher Receives Awards for Community Contributions and Neuroendocrine Tumor Research
• Talks with Docs: Heloisa Soares, GI Oncologist